Impact Factor
2.73
Journal Citation Impact
Estimated influence, citation density, publishing volume, and citation integrity from the analytics table.
Citation rate
1.59
133 total citations
h5-index
13
h5 depth signal
Cited share
69.8%
60 of 86
Total citations
133
Citation footprint
Metric signal
1.36
External metric anchor
Self-citation
3.0%
4 self-citations
Citations Trend
Monthly Publications Cadence
Citing Geographic Demographics
Japan
358
United States
8
China
5
India
3
South Korea
2
Citing Fields of Research
Lymphomas
305
Hematology
90
Immunology
50
Auto-Inflammatory Disorders
33
Palliative Care
17
Publishing Activity & Reach
Volume, recency, access pattern, and citing-community signals from the journal analytics record.
All-time article footprint
672
Articles tracked across the journal lifetime
Indexed publication set
86
60 cited publications
Last 12 months
40
40.0 publications/month
Open access share
87.5%
35 OA publications in the last year
Leading citing country
Japan
358 citing publications
Leading citing field
Lymphomas
305 citing publications
Latest tracked publication
1 January 2026
10 recent records available
Coverage & Indexing History
v46n1, Mar. 2006-
v46n1, Mar. 2006-
Active Coverage
Research Focus & Classification
Indexed Subjects
Lymphomas
Issuing & Sponsoring Bodies
Contributor
Nihon Rinpa Mōnaikei Gakkai
Broad Categories
Hematology
Pathology
Lymphomas
MeSH Descriptors
Hematologic Diseases
Lymphoma
Latest Publications
Recent article records with DOI-first linking and condensed abstracts.
01
DOI 10.3960/jslrt.26049
Open DOI
Anaplastic lymphoma kinase-positive large B-cell lymphoma presenting as a submucosal tumor-like lesion at the esophagogastric junction: a diagnostic pitfall
Anaplastic lymphoma kinase (ALK)-positive large B-cell lymphoma (LBCL) is a rare, aggressive variant of diffuse LBCL with an immunoblastic/plasmablastic morphology, a plasmacytic immunophenotype with loss of conventional B-cell antigens,...
02
DOI 10.3960/jslrt.26031
Open DOI
Fatal TAFRO syndrome in which adrenal hemorrhage preceded thrombocytopenia
TAFRO syndrome is a rare systemic inflammatory disease characterized by thrombocytopenia, anasarca, fever, renal dysfunction, and myelofibrosis, and its follows a rapidly fatal clinical course. A few cases of TAFRO syndrome complicated b...
03
DOI 10.3960/jslrt.26037
Open DOI
ER stress-associated apoptosis and pyroptosis-like changes in Kikuchi–Fujimoto disease
Access full-text academic articles: J-STAGE is an online platform for Japanese academic journals.
04
DOI 10.3960/jslrt.26035
Open DOI
Biopsy-proven inflammatory pulmonary opacities mimicking lymphoma relapse after CD19 CAR-T-cell therapy
Pulmonary lesions that newly emerge after chimeric antigen receptor T-cell therapy may raise immediate concern for lymphoma relapse, especially when they occur at sites of prior disease involvement. We report a patient with refractory di...
05
DOI 10.3960/jslrt.26029
Open DOI
Retained epcoritamab activity despite routine CD20 assay negativity approximately one terminal half-life after mosunetuzumab in B-cell lymphoma
CD20 testing shortly after CD20-directed therapy can be difficult to interpret. We report an 89-year-old woman with multiply relapsed B-cell lymphoma who underwent excisional biopsy of an enlarging right axillary lymph node 17 days after...
06
DOI 10.3960/jslrt.26027
Open DOI
Clonality patterns of IGH and TCRB gene rearrangement across lymphoma and non-lymphoma: a pitfall in the interpretation of multiplex PCR
Clonality testing using BIOMED-2-based multiplex PCR is widely applied in routine diagnostics, but its interpretation can be complicated by clonal-like peaks arising from non-neoplastic immune responses. In this study, we retrospectively...
07
DOI 10.3960/jslrt.26023
Open DOI
A case of diffuse large B-cell lymphoma achieving complete remission with epcoritamab after pseudoprogression
Although the use of bispecific antibodies for relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) is expanding, reports of pseudoprogression following this therapy are scarce. A 58-year-old, male patient with DLBCL achieved a c...
08
DOI 10.3960/jslrt.26032
Open DOI
Successful treatment of refractory hemophagocytic lymphohistiocytosis complicating Epstein–Barr virus-positive classic Hodgkin lymphoma with rituximab
Hemophagocytic lymphohistiocytosis (HLH) complicating classic Hodgkin lymphoma (HL-HLH) is a rare but frequently life-threatening condition that is strongly associated with Epstein–Barr virus (EBV) infection, particularly in the mixed-ce...
09
DOI 10.3960/jslrt.26017
Open DOI
Comparison of Pola-R-CHP and R-CHOP for newly diagnosed DLBCL: A single-center retrospective study
Background Polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisolone (Pola-R-CHP) has become a first-line treatment option for diffuse large B-cell lymphoma (DLBCL), but real-world data remain limited. We retros...
10
Background Brentuximab vedotin plus cyclophosphamide, doxorubicin, and prednisone (BV-CHP) has demonstrated survival benefits over cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) in patients with CD30-positive periphera...
Bibliographical & Catalog Notes
Title from cover.
Print issues ceased with v. 55, no. 3 (2015).
Also issued online.
Journal of the Japanese Society for Lymphoreticular Tissue Research, Oct. 2001- .
v. 47, no. 1 (Mar. 2007)20060921 Notice not published Printed on acid-free paper